Source/Disclosures
Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nahen is the CEO of Notal Vision.
November 12, 2020
27 min listen
Save

AI and Telemedicine for the Retina Specialist

Source/Disclosures
Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nahen is the CEO of Notal Vision.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this episode, Kester Nahen, PhD, discusses the use of artificial intelligence and telemedicine among retina specialists. We also review Notal Vision’s ForseeHome device and the company’s Home OCT AI-enable platform for monitoring AMD.

  • Intro :14
  • In this episode :21
  • About Dr. Nahen 1:24
  • The interview 1:42
  • The background of Kester Nahen 2:00
  • Nahen’s thoughts on the current state of telemedicine and artificial intelligence 5:10
  • Will artificial intelligence replace the clinical aspect of what we do? 7:42
  • About Notal Vision’s ForseeHome Device 9:30
  • The AMD criteria required for use of ForseeHome 11:54
  • As a result of COVID-19, has there been an increased interest in using ForseeHome? 13:15
  • What is the best way for ophthalmologists and eyecare providers to get more information about the ForseeHome program? 14:40
  • More details on Notal Vision’s Home OCT and will it really change and revolutionize the way retina specialists monitor patients? 16:00
  • What’s the status of the FDA approval process for the Home OCT? 21:10
  • What does Nahen think is the most important topic facing the ophthalmology industry today and what will be in the future? 23:05
  • Nahen’s final thoughts 25:30

Kester Nahen, PhD, is the chief executive officer at Notal Vision.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.